We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Panel of Research-Use-Only Mass-Spec Biomarker Tests Launched at AACC 2015

By LabMedica International staff writers
Posted on 12 Aug 2015
Print article
Over 50 research-use-only (RUO) mass-spectrometry based biomarker tests, to be offered as a laboratory service, were launched during the 2015 AACC Meeting & Clinical Lab Expo (July 26–30; Atlanta, GA, USA). The RUO tests are specifically designed for detection and quantification of key protein biomarkers in human serum or plasma and are available to pharmaceutical companies for clinical trials, researchers, and as companion diagnostics.

Nuclea Biotechnologies, Inc. (Pittsfield and Cambridge, MA, USA) highlighted this new service offering available in addition to services from their CLIA/CAP-certified clinical labs.

Companion diagnostics can facilitate development and approval of novel therapeutic drugs and are becoming necessary for successful outcome in many clinical trials. “With the advent of monoclonal antibody and other protein-based drugs, it has become crucial for researchers to access precise companion diagnostic assays for targeted proteins. Mass-spectrometry based tests can selectively detect and quantify protein drug targets at the sequence level,” said Dr. Mary F Lopez, COO and VP of Proteomics Discovery, Nuclea.

Nuclea’s first clinical service laboratory, in Pittsfield, MA (USA), offers an array of fully validated and reimbursable IHC and ELISA tests for various cancer-associated proteins in tissue and blood. Nuclea will launch a second, high-complexity CLIA lab in their Cambridge, MA (USA) facility in late 2015. In addition to IHC and ELISA tests, this lab will offer state-of-the-art mass-spectrometry based multiplexed assays for serum or plasma proteins associated with diabetes, metabolic syndrome, and obesity. “This new service offering is a direct result of our ability to recruit a renowned team of experts in mass spectrometry,” said Patrick Muraca, president and CEO, Nuclea, “We know that biomarkers play a key role in drug development and that there is a market for these services to support clinical research.”

Related Links:

Nuclea Biotechnologies
American Association for Clinical Chemistry (AACC)
AACC 2015 Annual Meeting & Clinical Lab Expo


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Signs of multiple sclerosis show up in blood years before symptoms appear (Photo courtesy of vitstudio/Shutterstock)

Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset

Autoimmune diseases such as multiple sclerosis (MS) are thought to occur partly due to unusual immune responses to common infections. Early MS symptoms, including dizziness, spasms, and fatigue, often... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: A new study has identified patterns that predict ovarian cancer relapse (Photo courtesy of Cedars-Sinai)

Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse

High-grade serous ovarian carcinoma is the most lethal type of ovarian cancer, and it poses significant detection challenges. Typically, patients initially respond to surgery and chemotherapy, but the... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.